southampton joint formulary - uhs
TRANSCRIPT
Cumulative update - Jul 2019CUMULATIVE UPDATE
This document is a cumulative list summarising changes to the Southampton
Joint Formulary. To check the current status of a medicine please refer to
www.southamptonformulary.nhs.uk
status
BNF
section
discontinued Feb 2017.
dexamethasone for multiple
physiotherapist or respiratory
of patients, and routine
carried out in secondary
urgent supply of
(e.g. Flutter, RC-Cornet,
status
BNF
section
Solent Sexual Health Service.
cervical block to facilitate
patients intolerant to paraffin-
paraffin-free emollients.
fire risks also apply to paraffin-
free emollients.
theatres only, or for adults if
ketorolac injection not
instructions on
administration by IV infusion.
Use in children is off label.
Amend
patients.
children and adolescents with
19/6/19 Rosuvastatin tabs Green 2.12 Reserved for use in patients
requiring high intensity statin
simvastatin
Add
19/6/19 Hyaluronic acid gel Red 7.5 For localised use in the uterus
only, for prevention of
status
BNF
section
England specialised
divisional pharmacist.
treatment of Wilson's disease
in accordance with NHS
divisional lead pharmacist.
advanced unresecatble non-
primary progressive multiple
metastatic non-squamous
and a DPP-4 inhibitor for
treating type 2 diabetes
19/6/19 Inotersen inj [Tegsedi] Red 9.8.1 NICE HST9: for treating
hereditary transthyretin
status
BNF
section
linked hypophosphataemia in
Add
advanced renal cell
carcinoma, with ipilimumab.
Available through Cancer
in the managed access
22/5/19 Abemaciclib tabs Red 8.1.5 NICE TA579: for HR+, HER2-
advanced breast cancer (with
22/5/19 Brentuximab vedotin inj Red 8.1.5 NICE TA577: for CD-30+
cutaneous T-cell lymphoma
attacks in hereditary
in patients with non-
treatment of HER 2-positive
early stage breast cancer
advanced non-small cell lung
24/4/19 Ertugliflozin tabs Green 6.1.2.3 NICE TA572: for type 2
diabetes, as monotherapy or
status
BNF
section
treated multiple myeloma,
with bortezomib and
24/4/19 Certolizumab pegol Red 13.5.3 NICE TA574: for moderate to
severe plaque psoriasis
severe plaque psoriasis
UHS diabetes team for new
patients. May be continued in
established patients.
25/3/19 Safinamide tabs Red 4.9.1 Supported by DPC June 2018
– awaiting shared care
tolerated.
Add
20/3/19 Ulipristal tabs [Esmya] Red 6.7.2 Amended from amber to red
in view of MHRA safety
update Aug 2018
untreated, HR-positive, HER2-
for unresectable or metastatic
for previously treated CLL
eosinophilic asthma
status
BNF
section
(Fixapost) as preservative-
developing allergy since
NHSE Clinical Commissioning
27/2/19 Lais® 1,000 AU
import).
alternatives are not suitable
status
BNF
section
have been treated in line
with NICE CG173:
experiencing pain associated
operation arrangement with
Pain Prescribing
pain (section 15.02).
postoperative analgesia in
advanced hepatocellular
treatment of completely
resected melanoma with
advanced hepatocellular
myeloid leukaemia
status
BNF
section
treatment of resected
recurrence (available through
Cancer Drugs Fund)
TA557: for untreated,
standard tablets are not
suitable or practical, e.g.
lower strengths, i.e. 0.5mg,
cutter.
Add
11.12.18.
Remove
(except paediatric uveitis).
moderately to severely active
status
BNF
section
Calm]
for otitis externa
(remains amber for ocular
SGLT-2 inhibitor for patients
and possible benefits for all 3
licensed drugs in this class
Amend
4.8.1
for neuropathic pain and
anxiety (remains amber for
leukaemia (CD-33 positive,
England commissioning policy
24/10/18 Bezafibrate MR tab Amber 2.12 Additional use off-label for
treatment of primary biliary
of toxicities associated with
Date Drug and formulation Colour
status
BNF
section
24/10/18 Cabozantinib tab Red 8.1.5 TA 542: Advanced renal cell
carcinoma
Amend
arthritis
Amend
V600 +ve melanoma
paediatrics. Red for transplant
indications, amber for all
classical Hodgkin lymphoma
leukaemia
Add
29/08/18 Aprepitant liquid Red 4.6 Prevention of N+V with highly
and moderately emetogenic
chemotherapy in children
separate constituents. 50
quadruple therapy.
where aminoglycoside should
concerns. Added in line with
MHRA restrictions.
29/08/18 Levonorgestrel IUS
29/08/18 Golimumab inj Red 1.5.3 Additional indication for use in
Crohn’s disease.
status
BNF
section
children and adolescents with
in line with guidelines.
difficulty crushing tablets
29/08/18 Piracetam tablets Amber 4.8.1 In line with NICE guidance.
Add
29/08/18 Stiripentol capsules Amber 4.8.1 To add for use in adults in line
with NICE guidance.
Add
29/08/18 Oxycodone injection Amber 4.7.2 Amber for use in palliative
care
Amend
COPD
Add
29/08/18 Enoxaparin injection Amber 2.8.1 Change from red to amber for
extended thromboprophylaxis
29/08/18 Ocrelizumab infusion
Red 8.2.4 TA533:Relapsing-remitting
atopic dermatitis
29/08/18 Alectinib capsules
29/08/18 Ixekizumab injection
29/08/18 Dinutuximab beta
29/08/18 Emicizumab inj
in people with congenital
inhibitors.
Add
29/08/18 Idebenone capsules Red 11.8.1 For DMD as part of EAMS.
Add
endorsed by DPC. Prescribe
status
BNF
section
endorsed by DPC. Prescribe
Add
18/07/18 Parecoxib injection Red 10.1.1 For use in palliative care by
CSCI as per palliative care
formulary. Endorsed by DPC.
18/07/18 Ondansetron tablets Green 4.6 Change from amber to green
endorsed by DPC.
18/07/18 Intranasal diamorphine Red 4.7.2 For severe acute pain in
paediatric patients in ED.
for patients unable to swallow
clopidogrel.
Add
replace Epaderm ointment.
Red 4.8.1 For NBM patients. Add
18/07/18 Guselkumab inj Red 13.5.3 TA 521: For plaque psoriasis Add
18/07/18 Pembrolizumab inj Red 8.1.5 TA 522: For metastatic
urothelial carcinoma when
18/07/18 Midostaurin capsules Red 8.1.5 TA 523: For FLT-3 +ve
myeloid leukaemia
Add
18/07/18 Brentuximab vedotin inj Red 8.1.5 TA 524: For CD-30 +ve
Hodgkin lymphoma
urothelial carcinoma after
18/07/18 Arsenic trioxide infusion Red 8.1.5 TA 526: For promyelocytic
leukaemia
Add
18/07/18 Beta-interferon injection Red 8.2.4 TA 527: For multiple sclerosis Amend
18/07/18 Glatiramer acetate Red 8.2.4 TA 527: For multiple sclerosis Amend
Date Drug and formulation Colour
status
BNF
section
18/07/18 Niraparib capsules Red 8.1.5 TA 528: For fallopian tube
and peritoneal cancer
Amend
urothelial cancer
25.06.18 Pegvisomant inj Red 6.8.1 As per commissioning criteria Add
25.06.18 Sildenafil liquid Red 2.5.1 For pulmonary hypertension
in line with specialised
25.06.18 Zafirlukast tabs Amber 3.3.2 Discontinued by
manufacturers
Remove
recommended for prescribing
eye gel
23/05/18 Pembrolizumab inf Red 8.1.5 TA 519: For locally advanced
or metastatic urothelial
23/05/18 Atezolizumab inf Red 8.1.5 TA 520: For locally advanced
or metastatic non-small-cell
care.
Add
25/04/18 Cabozantinib caps Red 8.1.5 TA 516: For medullary thyroid
cancer
Amend
status
BNF
section
25/04/18 Avelumab inj Red 8.1.5 TA 517: For metastatic Merkel
cell carcinoma
Add
25/04/18 Tocilizumab inj Red 10.1.3 TA 518: For giant cell ateritis Amend
25/04/18 Levofloxacin tab Red 5.1.2 In line with trust guidelines
and for prophylaxis in newly
diagnosed myeloma patients
warnings
Remove
warnings
Remove
formulation, for existing IPF
patients already on treatment
hepatitis C in adults
28/03/18 Pertuzumab inj Red 8.1.5 NICE TA 509 – In combination
with trastuzumab and
28/03/18 Daratumumab inj Red 8.1.5 NICE TA 510 – For relapsed
or refractory multiple
28/03/18 Brodalumab inj Red 13.5.3 NICE TA 511 – Moderate to
severe plaque psoriasis
renal cell carcinoma
follicular lymphoma
microbiology advice only
(For scabies - unlicensed)
(Added to formulary again
relapsed/refractory mantle
cell lymphoma
22.02.18 Ceritinib cap Red 8.1.5 TA500: For ALK positive non
small cell lung cancer
status
BNF
section
22.02.18 Everolimus tab
advanced renal cell carcinoma
22.02.18 Lenvatinib cap [Kisplyx] Red 8.1.5 TA498: with everolimus for
advanced renal cell carcinoma
axial spondyloarthritis
relapsed/refractory multiple
pulmonary fibrosis (replaces
recommended by DPC Feb
Southampton Children’s
fluid of choice.
but several patients admitted
formulary.
Add
patients at UHS.
for migraine prophylaxis
status
BNF
section
only.
moderate to severe atopic
systemic immunosupressants.
option.
unable to swallow
Add
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist
commission criteria
advanced or metastatic
remitting MS
metastatic breast cancer
or metastatic breast cancer
17.01.18 Aprotinin infusion Red 2.11 Restricted to use by Cardio-
thoracic anaesthetist only
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist
commission criteria
commission criteria
tumours
Add
and neck
status
BNF
section
13.12.17 Ibrutinib cap Red 8.1.5 TA 491 – For Waldenstrom’s
macroglobulinaemia
Amend
13.12.17 Thiotepa inj Red 8.1.5 For treatment of CNS diffuse
large B cell lymphoma
for bile acid malabsorption
and oxcarbazepine
13.12.17 Omega 3 capsule Red 2.12 Removed
29.11.17 Dexmedetomidine inj Red 15.1.4.4 Restricted for use for sedation
to NeuroICU consultant only
29.11.17 Ketamine 100mg/ml IM
restricted to senior
ED/anaesthetic registrars and
29.11.17 Brinzolamide/timolol eye
29.11.17 Bimatoprost/timolol eye
Amber 11.6 DPC approved 10/10/2017 Add
29.11.17 Cladribine tab Red 8.1.3 For use in MS in line with
specialised commissioning
treated squamous and non-
severe rheumatoid arthritis
neovascularisation in adults
01.11.17 Roflumilast tab Amber 3.3.2 As per DPC 10/2017 Amend
Date Drug and formulation Colour
status
BNF
section
01.11.17 Enoxaparin inj Various 2.8.1 Note added to prescribe by
brand name as biosimilar
use
Amend
01.11.17 Optho-Lique eye drops Green 11.8.1 Add
01.11.17 Ropinirole MR tab Amber 4.9.1 Add
01.11.17 Ceftazidime/ Avibactam
cartilage defects of the knee
Add
refractory systemic anaplastic
Amend
eosinophillic asthma
severe rheumatoid arthritis
11.10.17 Neomycin eye oint Green 11.3.1 Removed from formulary as
formulation discontinued
27.09.17 Eluxadoline tab Amber 1.2 TA 471 Add
27.09.17 Oralvac compact
Second line therapy if Pollinex
not suitable
of priapism
27.09.17 Paclitaxel albumin inj Red 8.1.5 TA 476 Add
Date Drug and formulation Colour
status
BNF
section
TA 473 Amend
12.09.17 Ambrisentan tab Red 2.5.1 Only for patients already
commenced on therapy by
commenced on therapy by
criteria set by NHS England
Add
12.09.17 Cidofovir inf Red 5.3.2.1 For use as per commissioning
criteria set by NHS England
Add
criteria set by NHS England
Add
12.09.17 Deferasirox disp tab Red 9.1.3 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Deferiprone tab Red 9.1.3 For use as per commissioning
criteria set by NHS England
Add
criteria set by NHS England
Add
12.09.17 Icatibant inj Red 3.4.3 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Plerixafor inj Red 9.1.7 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Sodium oxybate liq Red 4.1.1 For use in children as per
commissioning criteria set by
08.09.17 Dermol 500 lotion Green 13.2.1 Additional information “Note:
this contains an antimicrobial.
Not recommended for long-
blue.
Amend
status
BNF
section
Amended further information
as blue.
as blue.
once-daily dosing not
considered as non-formulary).
(licensed has been
discontinued, only available
licensed formulation (caps
maximum doses, as NICE no
longer specifies. Removed
updated and replaced by
foam in light of price increase
Add
Remove
30.08.17 Buspirone tab Amber 4.1.2 Change from red to amber
approved by DPC
Remove
approved by DPC
status
BNF
section
Comments Action
30.08.17 Insulin Aspart [Fiasp] inj Amber 6.1.1.1 Recommended by DPC. For
specialist recommendation.
30.08.17 Glucodrate powder Amber 9.2.1.2 Replacing St Mark’s solution.
Approved by DPC
30.08.17 Ketocal liquid N/A 9.4 Replacing ketocal powder Add
30.08.17 Anamix feeds N/A 9.4
Add
vaccine on routine schedule
schedule from Autumn 2017
30.08.17 Cabozantinib tab Red 8.1.5 TA 463 – For advanced renal
cell carcinoma in adults after
VEGF-targeted therapy
Add
30.08.17 Olaratumab inj Red 8.1.5 TA 465 – For use within the
CDF as an option for soft
tissue sarcoma
30.08.17 Baricitinib tab Red 10.1.3 TA 466 – An option for
moderate to severe RA
glucose tolerance test due to
reduced glucose content
difficulties
Add
26.07.17 Oxycodone capsules Green 4.7.2 For patients unable to tolerate
liquid. Not for ward stock
Add
26.07.17 Hydrocortisone,
status
BNF
section
guidelines previously
orally where capsules are
unable to be given
26.07.17 Ustekinumab inj Red 1.5.3 TA 456 Amend
26.07.17 Pembrolizumab inj Red 8.1.5 TA 447 Amend
26.07.17 Etelcalcetide inj Red 9.5.1.2 TA 448 Add
26.07.17 Everolimus tab and
26.07.17 Blinatumomab inj Red 8.1.5 TA 450 Add
26.07.17 Ponatinib tab Red 8.1.5 TA 451 Add
26.07.17 Carfilzomib inj Red 8.1.5 TA 457 Add
26.07.17 Trastuzumab emtansine
26.07.17 Collagenase clostridium
26.07.17 Adalimumab
28.06.17 Diphenylcyclopropenone
previously agreed at DPC
specials list, previously
agreed at DPC
paste 0.1% - 15% w/w
specials list, previously
agreed at DPC
specials list, previously
agreed at DPC
status
BNF
section
specials list, previously
agreed at DPC
previously agreed at DPC
previously agreed at DPC
specials list, previously
agreed at DPC
28.06.17 Eosin solution 2% Red 13.12 Unlicensed ; as per BAD
specials list, previously
agreed at DPC
shared care agreement ‘off-
recurrence of breast cancer.
clinic.
use without specialist support.
28.06.17 Similac Alimentum N/A 9.4 Formula milk for CMPA. On
infant guidelines, cheaper
28.06.17 Nutramigen 1 and 2 N/A 9.4 Replaced by Similac
Alimentum
Remove
28.06.17 Certolizumab pegol inj Red 10.1.3 TA 445 Amend
28.06.17 Secukinumab inj Red 10.1.3 TA 445 Amend
Date Drug and formulation Colour
status
BNF
section
28.06.17 Levosimendan inj Red 2.1 Specialist use only Add
28.06.17 Obeticholic acid tab Amber 1.9.1 NICE TA 443 Add
24.05.17 Dexamethasone soluble
removed from formulary. No
prescribed by GPs
24.05.17 Amiclair protein remover Red 11.9
24.05.17 Saline spray Red 11.9
24.05.17 Boston advance Red 11.9
24.05.17 Netupitant/Palonosetron
[Akynzeo] capsules
Red 4.6
24.05.17 Fondaparinux inj Red 2.8.1 New indication for superficial
thrombophlebitis
Amend
recommendation
Add
24.05.17 Daclizumab inj Red 8.2.4 NICE TA 441 Add
24.05.17 Ixekizumab inj Red 13.5.3 NICE TA 442 Add
19.04.17 Adapalene 0.1%,
benzoyl peroxide 2.5%
vulgaris. Positive
19.04.17 Pilocarpine eye gel Amber 11.6 Discontinued 2012. Not used
since then as alternative eye
drops are available
laryngotracheobronchoscopy
Amend
19.04.17 Diclofenac inj Red 15.1.4.2 Restricted to use in paediatric
theatres
Add
status
BNF
section
units/ml
out by specialists
30.03.17 Benzoyl peroxide 4%
replace with
item below
30.03.17 Benzoyl peroxide gel Green 13.6.1 To replace Brevoxyl (see
above)
Add
“Prescribe by brand name” as
new brand now available
new patients on Braltus brand
(lower cost).
13.6.2
formulary.
Remove
Useful for patients with dry,
sensitive skin and same cost
as gel.
only.
OTC.”
formula).
Amend
Date Drug and formulation Colour
status
BNF
section
01.03.17 Ivermectin cream Green 13.6.3 First line option for the
treatment of Papulopustular
31.01.17 Dasatinib, nilotinib and
31.01.17 Pomalidomide cap Red 8.1.5 NICE TA 427 Add
31.01.17 Pembrolizumab inf Red 8.1.5 NICE TA 428 Amend
31.01.17 Ibrutinib cap Red 8.1.5 NICE TA 429 Add
31.01.17 Sofosbuvir/velpatasvir
31.01.17 Mepolizumab inj Red 3.4.2 NICE TA 431 Add
31.01.17 Mannitol inhalation
bronchial
hyperresponsiveness
Add
patients with distal disease.
Second line treatment for
amber for all other
with other local organisations
(e.g. West Hants CCG,
status
BNF
section
14.12.201
6
14.12.201
6
14.12.201
6
Technologies guidance) 3
a steroid sparing agent at
step 4/5 of the BTS guidelines
Add
14.12.201
6
per chronic constipation
Pancrex V granules Amber 1.9.4 For use in patients who
require administration of
with severe myoclonic
14.12.201
6
14.12.201
6
14.12.201
6
14.12.201
6
14.12.201
6
Emtricitabine/tenofovir
tab
specialist only. As per local
commissioning arrangements
Remove branding
status
BNF
section
macrolide – follow guideline
23.11.201
6
23.11.201
6
26.10.201
6
Specialist initiation only for
Amend
26.10.201
6
26.10.201
6
number)
26.10.201
6
number)
26.10.201
6
number)
26.10.201
6
Talimogene
6.6).
at UHS.
UHS for patients with
Syndrome Protocol)
rhinitis where response to
status
BNF
section
an option for pre-operative
treatment of uterine fibroids
or for intermittent treatment
line therapies are
care only
indications)
Add
11.10.201
6
requested by DPC (safety
paediatric patients only.
primary care)
aciclovir eye oint is
other oral iron preparations
guidance/in response to
28.09.201
6
28.09.201
6
Date Drug and formulation Colour
status
BNF
section
2014
Remove
28.09.201
6
difficulties/enteral feeding
care only
17.08.201
6
17.08.201
6
17.08.201
6
patients already stabilised on
the one monthly depot.
those with swallowing
patients treated by the
17.08.201
6
17.08.201
6
17.08.201
6
17.08.201
6
17.08.201
6
centre, prior to capillary blood
gas sampling
status
BNF
section
17.08.201
6
17.08.201
6
therapy who become nil by
mouth
Add
17.08.201
6
shared care agreement with
the Royal Brompton hospital
22.6.2016 Brivaracetam tab/liq/inj Amber Not
listed
Add
22.6.2016 Cabazitaxel inj Red 8.1.5 NICE TA391 Add
22.6.2016 Canagliflozin,
dapagliflozin and
empagliflozin tablets
status
BNF
section
administration”
Amend
22.6.2016 5-aminolevulinic acid
11.6.2013
Add
22.6.2016 Mirabegron MR tab Green 7.4.2 NICE TA 290 – Listed as
green and amber on current
formulary, status should be
8.3.4.2
synonym for this medicine.
not meeting protein
requirements with standard
not meeting energy
requirements within the
enteral feed
supply to be initiated in
secondary care and then
continued in primary care.
status
BNF
section
added TA
TA91/222.
Amended,
Unlicensed product last used
number 20.4.16 Etanercept biosimilar inj
[Benepali]
20.4.2016 Nortriptyline tab Green 4.3.1 &
4.7.3
No longer recommended in
NICE Guidance or local
Remove TA132
23.3.2016 Nivolumab inj [Opdivo] Red 8.2.4 TA384 Added, with TA
number
status
BNF
section
13.5.3
confusion as biosimilar now
number
only.
tolerate danazol
able to obtain stocks of this
drug)
Added
status
BNF
section
only.
at UHS.
years)
Added
recommended locally for
2014, but not actioned.
psychiatric care.
2014, but not actioned.
17.2.2016 Esomeprazole inj Red 1.3.5 In UHS: Child Health only
[Pantoprazole remains as
patients]
Added
added TA
added TA
added TA
added TA
added TA
status
BNF
section
added TA
added TA
added TA
number
added TA
number
Added, with TA
dabigatran is required for
17.2.2016 Degarelix 120mg inj Red 8.3.4.2 Consultant urologist use only
as a SINGLE DOSE (240mg)
in patients with naive prostate
cancer who present with
added TA
status
BNF
section
added TA
added TA
TA373 Amended,
added TA
added TA
added TA
number
20.1.2016 Ingenol gel [Picato] Green 13.8.1 Status change from amber to
green
Amended
30.12.201
5
Specialist use only
Specialist
initiation/recommendation
only
Amended,
line option, but may be
considered for patients with
with kidney impairment (see
SGLT-2 inhibitor for patients
Now green for prevention of
fractures in patients with
status
BNF
section
Specialist use only
Oncology only
Oncology only
Specialist use only
by manufacturers.
tablets in patients with
nasogastric tubes or children”
licensed indications.
18.11.201
5
18.11.201
5
as now licensed as a POM.
Amended
02.11.201
5
02.11.201
5
as included in new COPD
Guidelines.
Amended
status
BNF
section
option as included in new
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
Oncology only
07.10.201
5
status
BNF
section
outpatient induction of labour
only for multiple sclerosis’
approved)
Amended
07.10.201
5
multiple sclerosis
Removed phrase ‘For
numbers
07.10.201
5
Lidocaine plaster Red 15.2 ‘Off label’ use at UHS for
management of traumatic rib
fractures (refer to protocol).
07.10.201
5
manufacturers
Removed
07.10.201
5
that only the eye ointment is
unlicensed (eye drops now
other brands of insulin
glargine for new patients)
status
BNF
section
as a licensed preparation is
now available (Bramox).
Removed wording “for
Only in conjunction with
main entry to allow
Amended.
(preservative-free)
Guidelines for Primary Care
Removed brand name
eye drops
(Brand name not specified in
main entry to allow
Amended.
main entry to allow
Amended.
status
BNF
section
Guidelines for Primary Care
Removed ‘Unlicensed’ as now
available as a licensed
Guidelines for Primary Care
Guidelines for Primary Care
Guidelines for Primary Care
Guidelines for Primary Care
added TA
that approved by NICE.
guideline
only in selected patients (e.g.
high risk of multiple or flat
tumours)
Added
02.09.201
5
number
status
BNF
section
number
02.09.201
5
NICE TA347.
of neuropathic pain ladder.
(Relatively high cost in
(Discussed at UHS Drugs
taken for DPC.
care therefore amitriptyline
remains first line)
preparation
preparation appears to
primary and secondary care)
Ferrous fumarate tab Green 9.1.1.1 Added phrase “First line oral
iron preparation”
Dermatology specialists no
“[Sinemet]” from main entry
other brands and generic
status
BNF
section
“[Stalevo]” from main entry
other brands now available.
clarification.
medicines should be
prescribed and supplied
patient is allergic to
option if patient is allergic to
commonly-used
preservatives”
Amended
Units/ml) as new, high
strength formulation now also
available (has same brand
Units/ml) as new, high
strength formulation now also
available (has same brand
Units/ml) as new, high
strength formulation now also
available (has different brand
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
status
BNF
section
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
NICE TA330
manufacturers (2013)
29.06.15 Obinutuzumab inj Red 8.2.3 NICE TA343 Added, with TA
number
NICE TA337.
number
number
number, and
colour for
DVT/PE)
29.06.15 Darifenacin tab Green 7.4.2 First or second line option for
urinary incontinence.
29.06.15 Vedolizumab inj Red 1.5.3 For ulcerative colitis.
Specialist use only.
status
BNF
section
to green
to green and removed
line for new patients
29.06.15 Dulaglutide inj Green 6.1.2.3 Not a first-line option, but
may be considered for
for patients with kidney
Amber 11.8.1 Removed brand name Amended
04.06.15 Fortisip Bottle 200ml N/A 9.4 Moved from section 2 to
section 1 of UHS feeds and
nutritional supplements
03.06.15 Ciclosporin eye
drops unavailable
Hospital, Southampton.
Amber for prevention of
wording (‘For
NICE TA331
NICE TA329
Added BNF
status
BNF
section
NICE TA329
Added wording,
added TA
number
NICE TA117
macular oedema
Added TA
number and
29.04.15 Empagliflozin tab Green 6.1.2.3 NICE TA336 Added with TA
number
25.03.15 Miconazole 100mg
25.03.15 Ethinylestradiol
30microgram and
Marvelon
Amended
Mercilon
Amended
25.03.15 GlucoRx blood glucose
and Wavesense Jazz/Jazz Duo
blood glucose test strips
glucose test strips
glucose test strips
patients taking tapentadol MR
status
BNF
section
patients meeting NHS
second-line subcutaneous
25.02.15 Dolutegravir tabs Red 5.3.1 Specialist use only Added
25.02.15 Lithium carbonate MR
with shared care guidelines
25.02.15 Saxagliptin tabs Green 6.1.2 Replaced by alogliptin Removed
25.02.15 Alogliptin tabs Green 6.1.2 To replace saxagliptin Added
25.02.15 Dabigatran tabs
the treatment and secondary
prevention of deep vein
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
status
BNF
section
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
2 of oral
2 of oral
status
BNF
section
28.01.15 Clinitest reagent tabs Discontinued by manufacturer Removed
07.01.15
(Decembe
r
meeting)
Erythropoiesis-
number 07.01.15
Imatinib tablets Red 8.1.5 According to NICE TA326 Added TA
number
07.01.15
(Decembe
r
meeting)
26.11.14 Dihydrocodeine MR
26.11.14 Tramadol MR
Date Drug and formulation Colour
status
BNF
section
26.11.14 Osvaren tablets
26.11.14 Co-codamol 30/500
Green 4.7.1 Changed from blue to green Changed
26.11.14 Ibuprofen gel Green 10.3.2 Changed from blue to green Changed
26.11.14 Metformin sachets Discontinued by
manufacturer. Some wards
Removed
20.10.14 Lenalidomide capsules Red 8.2.4 According to NICE TA322 Added
20.10.14 Carbamazepine
chewable tablets
(Tegretol Chewtabs)
29.9.14 Budesonide MDI Discontinued by manufacturer Removed
29.9.14 Adrenaline
(epinephrine) inhaler
[Primatene Mist]
echinocandin, caspofungin is
for stimulation of lactation,
licensed indications. Local
recommendation is 10mg
days, then stop. Contra-
indicated in patients with
status
BNF
section
1.9.14
(August
meeting)
BNF for
patients with Raynaud’s
phenomenon
Added
1.9.14
(August
meeting)
Choice of NRT patch Green 4.10.2 Change from NiQuitin CQ to
Nicorette Invisi patches
1.9.14
(August
meeting)
BNF
red
Changed
1.9.14
(August
meeting)
Co-amoxiclav
have failed to respond to, or
are intolerant of, other
options, or have psychological
distress due to persistent
redness. Cautious use is
available around long-term
effect with longer-term use.
worsening of their rosacea
status
BNF
section
1.9.14
(August
meeting)
Prasugrel tablets Amber 2.9 According to NICE TA317 Changed TA
number
1.9.14
(August
meeting)
1.9.14
(August
meeting)
1.9.14
(August
meeting)
1.9.14
(August
meeting)
formulary entry
mono-
falciparum malaria
falciparum malaria or as oral
step-down treatment
21.7.14 Emerade pre-filled pen Green 3.4.3 Supply problems with other
brands of adrenaline for self-
administration
Added
status
BNF
section
replaced by ‘unit dose eye
drops’ to allow purchasing of
different brands
craniotomy.
label status and lack of
comparative evidence and
an alternative
use only in Solent.
severe behavioural insomnia
30.6.14 Afatinib tablets Red 8.1.5 According to NICE TA310 Added
30.6.14 Bortezomib injection Red 8.1.5 According to NICE TA311 Added TA
number
in BNF
30.6.14 Alemtuzumab infusion Red 8.2.3 The old formulation of
alemtuzumab, used for bone
marrow transplant patients, is
named patient drug
30.6.14 Glyceryl trinitrate buccal
required
30.6.14 Forceval Junior Soluble Green 9.6.7 Replace formulation Changed from
Foreceval
primary care guideline
status
BNF
section
primary care guideline
amber to green
30.6.14 Dapagliflozin tablets Green 6.1.2.3 To be used in line with NICE
TA288
intolerant of preservatives
women with high BMI or
intrauterine device is declined
hours after intercourse)
formulary entry for nocturnal
cannot use other inhaler
dose to propionate 500
micrograms twice a day
COPD.
Note:
of neurological adverse
status
BNF
section
See MHRA Drug Safety
psychiatric care. Criteria for
use are being developed
28.4.14 Pixantrone injection Red 8.1.2 According to NICE TA306 for
non-Hodgkin’s lymphoma
28.4.14 Aflibercept injection Red 11.8.2 According to NICE TA305 for
macular oedema (central
retinal vein occlusion)
28.4.14 Rituximab infusion Red 8.2.3 According to NICE TA308 for
anti-neutrophil cytoplasmic
antibody-associated vasculitis
Added TA
10.1.3
Added
swallowing, who are nil by
mouth or who require
orally or through a gastric or
jejunal enteral feeding tube.
who are at risk of refeeding
syndrome, with poor wound
healing or who need
treatment for vitamin and
available and can be used
when clinicians choose to
prescribe off-label for patients
diabetic macular oedema
status
BNF
section
reported back to DPC
patients stabilised by
adequately responding to
treatment with monotherapy
in BNF
active relapsing-remitting
multiple sclerosis
20.1.14 Zoledronic acid 4mg
acid will replace pamidronate
16.12.13 Amoxicillin capsules Red 5.1.1.3 For patients with chronic low
back pain associated with
Modic type 1 changes
16.12.13 Fidaxomicin tablets Amber 5.1.7 Change from red to amber.
On advice of microbiology for
first episode of severe C. diff
on concomitant antibiotic or
16.12.13 Magnesium
16.12.13 Apomorphine injection Red for
new
patient
s
ordinated transfer to
16.12.13 Linaclotide capsules Amber 1.6.7 According to local algorithm Added
16.12.13 Immediate release
women or patients with
status
BNF
section
TA300 (hepatitis C, children
TA300 (hepatitis C, children
(choroidal neovascularisation
[pathological myopia])
(vitreomacular traction)
indications has been updated
(see end of document)
28.10.13 Mercaptopurine tablets Change
azathiorpine/mercaptopurine
macular degeneration
visual acuity <20/32).
preferred product as it is the
least expensive and contains
the correct combination of
vitamins and zinc. Unlike
longer contains beta-
no convincing evidence to
purchase these OTC.
normally initiated on
secondary care advice.
status
BNF
section
endoscopy for a specific group
of adults and children over 10
years who do not tolerate IV
cannulation (e.g. those with
the first line option for the
majority of patients
hypogonadism with marked
clinical symptoms of
nutrition
section
Added
2.9.13 Mirabegron tab Green 7.4.2 According to NICE TA290 Added NICE TA
number.
status
BNF
section
Comments Action
2.9.13 Ceftaroline inj Red 5.1.2 Only for specialist use on the
advice of microbiology
2.9.13 Eltrombopag tab Red 9.1.4 According to NICE TA293 Added
2.9.13 Eptotermin alfa
2.9.13 Dapagliflozin tab Amber 6.1.2.3 According to NICE TA288 Added
2.9.13 Aripiprazole tab Amber 4.2.1 According to TA292 (bipolar
disorder in children)
(pulmonary embolism and
fungal infections.
Note
which has been discontinued
29.7.2013 Calcium carbonate
unavailable
Added
29.7.2013 Hydroxyethyl starch
because large RCTs have
renal dysfunction and
septic patients who received
status
BNF
section
(FP10
use
only)
red to amber
red to amber
24.6.2013 Fidaxomicin tabs Red 5.1.7 Limited to patients with first
episode of severe C diff when
concurrent antibiotics cannot
episodes of C diff. On advice
of microbiology
degeneration according to
specialists
subtrochanteric fractures
Change
24.6.2013 Omalizumab inj Red 3.4.2 According to NICE TA278 Update NICE
TA number
(macular oedema)
24.6.2013 Pirfenidone caps Red 3.11 According to NICE TA282 Added
24.6.2013 Abatacept inj Red 10.1.3 According to NICE TA280
(rheumatoid arthritis)
Update NICE
TA number
status
BNF
section
20.5.13 Adcal chewable tab Green 9.5.1.1 Will replace Calcichew Changed
20.5.13 Adcal D3 effervescent
Green 9.6.4 Will replace Calfovit sachets Changed
20.5.13 Adcal D3 chewable tab Green 9.6.4 Will replace Calcichew D3
Forte
Changed
cannot tolerate chewable or
20.5.13 Oxazepam tab Amber 4.10.1 For use according to the
emergency department policy
on alcohol misuse
29.4.13 Dabigatran cap Green 2.8.2 Previously amber for
prevention of stroke in
green as GPs don’t refer these
patients to a specialist
prevention of stroke in
green as GPs don’t refer these
patients to a specialist
29.4.13 Apixaban tab Green 2.8.2 NICE TA275 for prevention of
stroke and systemic embolism
in patients with non-valvular
macular oedema
publication of NICE TA
receptor agonist for new
patients instead of exenatide
specialist for difficult to
diabetes
Added
29.4.13 Linagliptin tab Green 6.1.2.3 For patients with any stage of
renal impairment
status
BNF
section
Cerazette
Added
29.4.13 Octasa MR tab Amber 1.5.1 New name for Mesren Changed
29.4.13 Halothane Red 15.1.2 Has been discontinued Remove
25.2.13 Testosterone patch Blue 6.4.2 Had been discontinued, but
now available from a new
supplier
Re-instated
25.2.13 Choriogonadotropin alfa
25.2.13 Fluticasone and
patients age 6 and over with
cystic fibrosis and G551D
abstinence in alcohol
which device the patient can
use and cost
which device the patient can
use and cost
25.2.13 Voractiv tab Red 5.1.9 As complete courses of drugs
for TB are managed by the
hospital, all drugs in section
5.1.9 of the formulary will
become ‘red’
Added Voractiv.
5.1.9 amended
status
BNF
section
25.2.13 Argatroban inj Red 2.8.1 An option for patients in
critical care areas with
25.2.13 Eplerenone tab Amber 2.2.3 To reduce the risk of
cardiovascular mortality and
25.2.13 Ipilimumab infusion Red 8.1.5 According to NICE TA268 Added
25.2.13 Vemurafenib tab Red 8.1.5 According to NICE TA269 Added
25.2.13 Mannitol caps for
21.1.13 Ivabradine tab Amber 2.6.3 According to NICE TA267 Updated
21.1.13 Methylthioninium
during surgery.
Methylthioninium chloride
patients with
21.1.13 Darunavir liquid Red 5.3.1 GUM and Child Health
specialists only
of abstinence in alcohol
formulary. Now in 6.1.5 too,
for use in patients with
hyperhidrosis
Updated
radionuclide DOTATATE
Geltears
Updated
status
BNF
section
during surgery.
Methylthioninium chloride
patients with
malathion aqueous liquid,
green
Updated
12.11.12 Glatiramer injection Red 8.2.4 As part of the Department of
Health’s risk sharing scheme
for patients with multiple
15.10.12 Alteplase injection Red 2.10.2 Update to NICE guidance for
acute ischaemic stroke. Now
15.10.12 Prucalopride tablets Amber 1.6.7 According to shared care
guideline (available from
transfer from Epipen to Jext
(this device has a longer shelf
life)
Added
ed
secondary care for small
number of patients with
formulary
status
BNF
section
on long-term TPN or IV fluids
Added
17.9.12 Naltrexone tablets Amber 4.10 For alcohol addiction Previously used
at Southern,
drops (Hylo-Tear &
allergy to preservatives
Added
17.9.12 Travoprost eye drops Amber 11.6 For patients with a proven
allergy to benzalkonium
17.9.12 Loteprednol eye drops Amber 11.4.1 Added
17.9.12 Ulipristal 5mg tablets Amber 6.4.1.2 An option for the pre-
operative treatment of uterine
used in primary care. Efudix
remains the first-line topical
treatment (awaiting update of
superseded by NICE
ointment
discontinued
Added
17.9.12 Rivaroxaban tablets Green 2.8.2 NICE TA261 -an option for
treating DVT and long-term
Added
17.9.12 Botulinum toxin type A Red 4.9.3 Option for chronic migraine
according to NICE TA260
prostate cancer after
locally advanced or metastatic
status
BNF
section
stroke and systemic embolism
according to NICE TA249
17.9.12 Calcitonin nasal spray 6.6 Being discontinued due to risk
of cancer
seizure disorder
Added
17.9.12 Prucalopride tablets Amber 1.6.7 Changed from red to amber Changed
17.9.12 Ticagrelor tablets Green 2.9 NICE TA236 Changed colour
17.9.12 Rituximab infusion Red 8.2.3 NICE TA226 Added
17.9.12 Bivalirudin injection Red 2.8.1 NICE TA230 Added
17.9.12 Thalidomide capsules Red 8.2.4 NICE TA228 Added
17.9.12 Phenobarbital elixir Red 4.8.1 Unlicensed special order
preparations are available,
an excipient. Specialist only
prescribing and supplied from
18.6.12 Indapamide tablets and
now discontinued)
18.6.12 Omalizumab injection Red 3.4.2 Although ‘red’ locally it was
agreed that in order to reduce
day case attendances the 6
local patients receiving this
to teaching self-
administration to these
Added
status
BNF
section
18.6.12 Boceprevir capsules Red 5.3.3.2 According to NICE TA253 Added
18.6.12 Nilotinib capsules Red 8.1.5 According to NICE guidance
(TA251) as an option for first
line treatment of chronic
Added
18.6.12 Standard dose imatinib Red 8.1.5 According to NICE TA251 as
an option for first line
treatment of chronic myeloid
TA247 for rheumatoid
patients e.g active patients,
Red 3.4.2 According to NICE TA246 Added
18.6.12 Fingolimod capsules Red 8.2.4 Only according to NICE TA254 Added
18.6.12 Proveblue injection Red 15.2 Licensed version of
methylthioninium chloride
cohort of patients, in line with
current low priorities guidance,
on a table; and there is functional
impairment.
flexion. Only to be administered
by hand surgeons trained in its
use. Restricted to cases where it
is likely that only a single
Added
status
BNF
section
18.6.12 Rituximab injection Red 10.1.3 According to agreed guidance for
adults with systemic lupus
18.6.12 Growth hormone Red 6.5.1 First line choices are Omnitrope
and Genotropin. Consider
Genotropin
Updated
the licensed indications for
protection issues, generic
pioglitazone has demonstrated
on an exceptional basis for heavy
menstrual bleeding
following specialist
recommendation only
Southern Health
who need a different device
Added
fractured neck of femur or who
have a plaster cast and who fulfil
the assessment criteria
Added
(unlicens
ed)
Missed off formulary previously Added 26.3.12 Laxido Green 1.6.4 Previously ‘blue’ but now changed
to ‘green’ to promote use in UHS
for adults with chronic
constipation or faecal impaction
status
BNF
section
27.2.12 Goserelin, leuprorelin,
treatment and for the
indications
Changed
27.2.12 Easyhaler Formoterol Green 3.1.1.1 Added
27.2.12 Nevirapine MR tablets Red 5.3.1 Added
27.2.12 Rotigotine patches Amber 4.9.1 Initiated/recommended by
specialists: as a replacement for
oral dopamine agonists in
patients with inadequate control
medication, motor problems) and
situations when patients are
Changed
by NICE guidance)
drops
27.2.12 Sterile talc kit Red Not in
BNF
27.2.12 Rituximab injection Red 8.2.3 NICE TA243 – follicular
lymphoma
Added
idiopathic arthritis
by NICE guidance)
Added
23.1.12 PelvicToner device Blue As part of pelvic floor training Added
23.1.12 Levonorgestrel tablet 30
23.1.12 Ticagrelor tablet Blue 2.9 NICE TA236 Added
23.1.12 Mifamurtide injection Red 8.2.4 NICE TA235 Added
23.1.12 Estradiol vaginal tablet
Blue 7.2.1 Added
23.1.12 Nicorette Icy White Green 4.10.2 As part of smoking cessation Added
Date Drug and formulation Colour
status
BNF
section
23.1.12 Nicorette Quickmist
programme
Added 23.1.12 Nicorette Inhalator Green 4.10.2 As part of smoking cessation
programme
Added
23.1.12 Capsaicin patch 8% Red 10.3.2 Only for patients with post-
herpetic neuralgia who have
options
Added
12.12.11 Aminophylline MR tablet Green 3.1.3 For existing patients Added
12.12.11 Ferric carboxymaltose
indication of peripheral nerve
infusion via peripheral nerve
14.11.11 Golimumab injection Red 10.1.3 NICE TA233 Added
14.11.11 Moxifloxacin tablet Amber 5.1.12 Already on the formulary for
restricted use. Formulary entry to
be amended to add use according
to guideline (adult ENT)
Amended
17.10.11 TriRegol tablet Blue 7.3.1 To replace Logynon Added 17.10.11 Rigevidon tablet Blue 7.3.1 To replace Ovranette Added
17.10.11 Millinette 30/75 tablet Blue 7.3.1 To replace Femodene Added
12.09.11 Ciclosporin eye drops Red 11.8.1 A special Added
12.09.11 Golimumab injection Red 10.1.3 NICE TA225 Added
12.09.11 Retigabine tablets
brand of botulinum is required
and indication
Pharmacy.
(Oxynorm) liquid (green) in
accordance with the formulary.
their supply of Oxycodone
status
BNF
section
19.07.11 Romiplostim
19.07.11 Naftidrofuryl capsule Green 2.6.4 NICE TA223 Added
19.07.11 Denosumab injection Amber 6.6.2
NICE TA204 Added
19.07.11 Naltrexone tablet
alcohol withdrawal in patients
alcohol detox service
swallow tablets
13.06.11 Raltegravir tablet Red 5.3.1 Prescribing should be carried out
be local HIV specialists only
13.06.11 Maraviroc tablet Red 5.3.1 Prescribing should be carried out
be local HIV specialists only
13.06.11 GlucoRx test strips Blue 6.1.6
13.06.11 Osvaren tablet Blue 9.5.2.2 Hyperphosphataemia of chronic
renal failure in patients
statement “for pancreatic and
09.05.11 Fondaparinux injection Red 2.8.1 As an adjunct to thrombolysis
with tenecteplase in STEMI
experienced adults
syndromes
Added
18.04.11 Saxagliptin tablet Green 6.1.2.3 Another option for Type 2
Diabetes. Can be used in patients
with moderate to severe renal
impairment
Added
Marvelon whilst in short supply
Added.
Amended
18.04.11 Pazopanib tablet Red 8.1.5 According to NICE TA215 Added
18.04.11 Bendamustine injection Red 8.1.1 NICE TA216 – lymphocytic
leukaemia
Added
- drugs for treatment after failure
Added
status
BNF
section
18.04.11 Sirolimus tablet Amber 8.2.2 Prevention of rejection in post
liver transplant patients
18.04.11 Rosiglitazone tablet Green 6.1.2 Withdrawn from the UK Market
November 2010
Microbiology approved treatment
of mycobacterium abcessus
psoriasis. Topical treatment of
plaque psoriasis.
tablets in patients with NG tubes
or paediatric patients. Tab and
caps already on formulary
21.03.11 Venlafaxine tablet Green 4.3.4 Only high dose is amber
{previously all doses amber}
21.03.11 Aripiprazole tablet Amber 4.2.1 NICE TA213 Prescribing in 15-17
year old: schizophrenia
information
prior to surgery on enhanced
recovery programme
21.02.11 Tafluprost eye drops Amber 11.6 Specialist use and
recommendation.
preservative free prostaglandin
corneal grafts
21.02.11 Melatonin tablet/capsule Amber 4.1.1 Cost effective first line choice is
Biomelatonin tabs, followed by
Melatonin Biotec caps
neurogenic bowel dysfunction
other treatments have failed, or
when incontinence is a problem
Added
21.02.11 Liraglutide injection Amber 6.1.2.3 According to NICE TA203 For
Date Drug and formulation Colour
status
BNF
section
21.02.11 Trastuzumab injection Red 8.1.5 Gastric cancer according to NICE
TA208
For
Information
13.12.10 Botulinum Toxin
cumulative update
3
Dietitia
n
request
18.10.10 Pollinex Quattro®
clinic’s use only
18.10.10 Rosiglitazone tablet Green 6.1.2.3 MHRA alert. Removed from UK
market 21.10.10
by trained professionals
18.10.10 Calcium phosphate
sachet (Calfovit D3®)
vitamin D3 forte for patients
unable to swallow tablets
Added
18.10.10 Fondaparinux injection Red 2.8.1 For NSTEMI (NICE CG94) Amended
18.10.10 Nutricia Pre-op
replacement on enhanced
{Geltears®}
Amended
Syndrome
cystic fibrosis.
carmellose drops (Celluvisc®)
preservatives is problematic
by NICE TA211)
status
BNF
section
Comments Action
13.09.10 Abidec® drops Green 9.6.7 Used by neonatal unit as an
alternative to Dalivit drops
13.09.10 Vinorelbine capsule Red 8.1.4 Reserved for patients with poor
venous access as part of a
second or third line
chemotherapy regimen. In all
other circumstances, and for
exceptional cases, an Individual
Funding Request may be
18.07.10 NuvaRing®
contraceptive device
18.07.10 Insulatard InnoLet® Green 6.1.1.2 Treatment of gestational diabetes
and type 2 diabetes in pregnancy
Added
18.07.10 Darunavir 400mg tablet Red 5.3.1 In combination with ritonavir for
antiretroviral naïve patients
To be used in line with “Protocol
for use of sugammadex”
sclerosis (previously
methylprednisolone sodium
administered orally)
Added
Removed
antiemetics
Amended
units
26.04.10 Remifentanil injection Red 15.1.4.3 Patient controlled analgesia for
labour
Amended
(previously
theatres
only)
Added
discharge
Added
instillation is greater than 6 times
daily. Complete course to be
provided on discharge from
26.04.10 Certolizumab pegol Red 10.1.3 Option in severe active Added
Date Drug and formulation Colour
status
BNF
section
tried methotrexate and another
DMARD, according to NICE:
26.04.10 Trabectedin injection Red 8.1.5 Soft tissue sarcoma according to
NICE:
http://guidance.nice.org.uk/TA185
Added
26.04.10 Ferrous fumarate tablet Green 9.1.1.1 Currently PCT use only, change to
green
Amended
26.04.10 Ferrous sulphate Green 9.1.1.1 Replaced by ferrous fumarate Removed
26.04.10 Triclofos liquid Red 4.1.1 Discontinued Removed
26.04.10 Amphotericin lozenges Green 12.3.2 Discontinued Removed
End of list
Portsmouth Area Prescribing Committee
Blepharospasm √ √ √
Cervical dystonias √ √ √ √
Focal spasticity √ (arm & foot) √ (foot & post stroke wrist/hand) √ (post stroke arm)
Hemifacial spasm √ √
Hyperhidrosis (severe) √
Migraine prophylaxis √
sclerosis
Unlicensed: Ophalmology
Induction of ptosis to treat corneal exposure problems or facial palsy
Treatment of early onset squint
EMG guided intra ocular inj for diagnostic purposes such as checking for binocular potential prior to squint surgery
EMG guided intra ocular inj for therapeutic purposes such as inj into medial rectus & transpose vertical recti for cases of
complete VI nerve palsy
Face & neck tics
Spasm of reconstructed pharynx after laryngectomy
Spastic dysphonia
Gastro
Approved by Basingstoke, Southampton & Winchester DPC and Portsmouth APC 2013
(9.13)
This document is a cumulative list summarising changes to the Southampton
Joint Formulary. To check the current status of a medicine please refer to
www.southamptonformulary.nhs.uk
status
BNF
section
discontinued Feb 2017.
dexamethasone for multiple
physiotherapist or respiratory
of patients, and routine
carried out in secondary
urgent supply of
(e.g. Flutter, RC-Cornet,
status
BNF
section
Solent Sexual Health Service.
cervical block to facilitate
patients intolerant to paraffin-
paraffin-free emollients.
fire risks also apply to paraffin-
free emollients.
theatres only, or for adults if
ketorolac injection not
instructions on
administration by IV infusion.
Use in children is off label.
Amend
patients.
children and adolescents with
19/6/19 Rosuvastatin tabs Green 2.12 Reserved for use in patients
requiring high intensity statin
simvastatin
Add
19/6/19 Hyaluronic acid gel Red 7.5 For localised use in the uterus
only, for prevention of
status
BNF
section
England specialised
divisional pharmacist.
treatment of Wilson's disease
in accordance with NHS
divisional lead pharmacist.
advanced unresecatble non-
primary progressive multiple
metastatic non-squamous
and a DPP-4 inhibitor for
treating type 2 diabetes
19/6/19 Inotersen inj [Tegsedi] Red 9.8.1 NICE HST9: for treating
hereditary transthyretin
status
BNF
section
linked hypophosphataemia in
Add
advanced renal cell
carcinoma, with ipilimumab.
Available through Cancer
in the managed access
22/5/19 Abemaciclib tabs Red 8.1.5 NICE TA579: for HR+, HER2-
advanced breast cancer (with
22/5/19 Brentuximab vedotin inj Red 8.1.5 NICE TA577: for CD-30+
cutaneous T-cell lymphoma
attacks in hereditary
in patients with non-
treatment of HER 2-positive
early stage breast cancer
advanced non-small cell lung
24/4/19 Ertugliflozin tabs Green 6.1.2.3 NICE TA572: for type 2
diabetes, as monotherapy or
status
BNF
section
treated multiple myeloma,
with bortezomib and
24/4/19 Certolizumab pegol Red 13.5.3 NICE TA574: for moderate to
severe plaque psoriasis
severe plaque psoriasis
UHS diabetes team for new
patients. May be continued in
established patients.
25/3/19 Safinamide tabs Red 4.9.1 Supported by DPC June 2018
– awaiting shared care
tolerated.
Add
20/3/19 Ulipristal tabs [Esmya] Red 6.7.2 Amended from amber to red
in view of MHRA safety
update Aug 2018
untreated, HR-positive, HER2-
for unresectable or metastatic
for previously treated CLL
eosinophilic asthma
status
BNF
section
(Fixapost) as preservative-
developing allergy since
NHSE Clinical Commissioning
27/2/19 Lais® 1,000 AU
import).
alternatives are not suitable
status
BNF
section
have been treated in line
with NICE CG173:
experiencing pain associated
operation arrangement with
Pain Prescribing
pain (section 15.02).
postoperative analgesia in
advanced hepatocellular
treatment of completely
resected melanoma with
advanced hepatocellular
myeloid leukaemia
status
BNF
section
treatment of resected
recurrence (available through
Cancer Drugs Fund)
TA557: for untreated,
standard tablets are not
suitable or practical, e.g.
lower strengths, i.e. 0.5mg,
cutter.
Add
11.12.18.
Remove
(except paediatric uveitis).
moderately to severely active
status
BNF
section
Calm]
for otitis externa
(remains amber for ocular
SGLT-2 inhibitor for patients
and possible benefits for all 3
licensed drugs in this class
Amend
4.8.1
for neuropathic pain and
anxiety (remains amber for
leukaemia (CD-33 positive,
England commissioning policy
24/10/18 Bezafibrate MR tab Amber 2.12 Additional use off-label for
treatment of primary biliary
of toxicities associated with
Date Drug and formulation Colour
status
BNF
section
24/10/18 Cabozantinib tab Red 8.1.5 TA 542: Advanced renal cell
carcinoma
Amend
arthritis
Amend
V600 +ve melanoma
paediatrics. Red for transplant
indications, amber for all
classical Hodgkin lymphoma
leukaemia
Add
29/08/18 Aprepitant liquid Red 4.6 Prevention of N+V with highly
and moderately emetogenic
chemotherapy in children
separate constituents. 50
quadruple therapy.
where aminoglycoside should
concerns. Added in line with
MHRA restrictions.
29/08/18 Levonorgestrel IUS
29/08/18 Golimumab inj Red 1.5.3 Additional indication for use in
Crohn’s disease.
status
BNF
section
children and adolescents with
in line with guidelines.
difficulty crushing tablets
29/08/18 Piracetam tablets Amber 4.8.1 In line with NICE guidance.
Add
29/08/18 Stiripentol capsules Amber 4.8.1 To add for use in adults in line
with NICE guidance.
Add
29/08/18 Oxycodone injection Amber 4.7.2 Amber for use in palliative
care
Amend
COPD
Add
29/08/18 Enoxaparin injection Amber 2.8.1 Change from red to amber for
extended thromboprophylaxis
29/08/18 Ocrelizumab infusion
Red 8.2.4 TA533:Relapsing-remitting
atopic dermatitis
29/08/18 Alectinib capsules
29/08/18 Ixekizumab injection
29/08/18 Dinutuximab beta
29/08/18 Emicizumab inj
in people with congenital
inhibitors.
Add
29/08/18 Idebenone capsules Red 11.8.1 For DMD as part of EAMS.
Add
endorsed by DPC. Prescribe
status
BNF
section
endorsed by DPC. Prescribe
Add
18/07/18 Parecoxib injection Red 10.1.1 For use in palliative care by
CSCI as per palliative care
formulary. Endorsed by DPC.
18/07/18 Ondansetron tablets Green 4.6 Change from amber to green
endorsed by DPC.
18/07/18 Intranasal diamorphine Red 4.7.2 For severe acute pain in
paediatric patients in ED.
for patients unable to swallow
clopidogrel.
Add
replace Epaderm ointment.
Red 4.8.1 For NBM patients. Add
18/07/18 Guselkumab inj Red 13.5.3 TA 521: For plaque psoriasis Add
18/07/18 Pembrolizumab inj Red 8.1.5 TA 522: For metastatic
urothelial carcinoma when
18/07/18 Midostaurin capsules Red 8.1.5 TA 523: For FLT-3 +ve
myeloid leukaemia
Add
18/07/18 Brentuximab vedotin inj Red 8.1.5 TA 524: For CD-30 +ve
Hodgkin lymphoma
urothelial carcinoma after
18/07/18 Arsenic trioxide infusion Red 8.1.5 TA 526: For promyelocytic
leukaemia
Add
18/07/18 Beta-interferon injection Red 8.2.4 TA 527: For multiple sclerosis Amend
18/07/18 Glatiramer acetate Red 8.2.4 TA 527: For multiple sclerosis Amend
Date Drug and formulation Colour
status
BNF
section
18/07/18 Niraparib capsules Red 8.1.5 TA 528: For fallopian tube
and peritoneal cancer
Amend
urothelial cancer
25.06.18 Pegvisomant inj Red 6.8.1 As per commissioning criteria Add
25.06.18 Sildenafil liquid Red 2.5.1 For pulmonary hypertension
in line with specialised
25.06.18 Zafirlukast tabs Amber 3.3.2 Discontinued by
manufacturers
Remove
recommended for prescribing
eye gel
23/05/18 Pembrolizumab inf Red 8.1.5 TA 519: For locally advanced
or metastatic urothelial
23/05/18 Atezolizumab inf Red 8.1.5 TA 520: For locally advanced
or metastatic non-small-cell
care.
Add
25/04/18 Cabozantinib caps Red 8.1.5 TA 516: For medullary thyroid
cancer
Amend
status
BNF
section
25/04/18 Avelumab inj Red 8.1.5 TA 517: For metastatic Merkel
cell carcinoma
Add
25/04/18 Tocilizumab inj Red 10.1.3 TA 518: For giant cell ateritis Amend
25/04/18 Levofloxacin tab Red 5.1.2 In line with trust guidelines
and for prophylaxis in newly
diagnosed myeloma patients
warnings
Remove
warnings
Remove
formulation, for existing IPF
patients already on treatment
hepatitis C in adults
28/03/18 Pertuzumab inj Red 8.1.5 NICE TA 509 – In combination
with trastuzumab and
28/03/18 Daratumumab inj Red 8.1.5 NICE TA 510 – For relapsed
or refractory multiple
28/03/18 Brodalumab inj Red 13.5.3 NICE TA 511 – Moderate to
severe plaque psoriasis
renal cell carcinoma
follicular lymphoma
microbiology advice only
(For scabies - unlicensed)
(Added to formulary again
relapsed/refractory mantle
cell lymphoma
22.02.18 Ceritinib cap Red 8.1.5 TA500: For ALK positive non
small cell lung cancer
status
BNF
section
22.02.18 Everolimus tab
advanced renal cell carcinoma
22.02.18 Lenvatinib cap [Kisplyx] Red 8.1.5 TA498: with everolimus for
advanced renal cell carcinoma
axial spondyloarthritis
relapsed/refractory multiple
pulmonary fibrosis (replaces
recommended by DPC Feb
Southampton Children’s
fluid of choice.
but several patients admitted
formulary.
Add
patients at UHS.
for migraine prophylaxis
status
BNF
section
only.
moderate to severe atopic
systemic immunosupressants.
option.
unable to swallow
Add
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist
commission criteria
advanced or metastatic
remitting MS
metastatic breast cancer
or metastatic breast cancer
17.01.18 Aprotinin infusion Red 2.11 Restricted to use by Cardio-
thoracic anaesthetist only
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist
commission criteria
commission criteria
tumours
Add
and neck
status
BNF
section
13.12.17 Ibrutinib cap Red 8.1.5 TA 491 – For Waldenstrom’s
macroglobulinaemia
Amend
13.12.17 Thiotepa inj Red 8.1.5 For treatment of CNS diffuse
large B cell lymphoma
for bile acid malabsorption
and oxcarbazepine
13.12.17 Omega 3 capsule Red 2.12 Removed
29.11.17 Dexmedetomidine inj Red 15.1.4.4 Restricted for use for sedation
to NeuroICU consultant only
29.11.17 Ketamine 100mg/ml IM
restricted to senior
ED/anaesthetic registrars and
29.11.17 Brinzolamide/timolol eye
29.11.17 Bimatoprost/timolol eye
Amber 11.6 DPC approved 10/10/2017 Add
29.11.17 Cladribine tab Red 8.1.3 For use in MS in line with
specialised commissioning
treated squamous and non-
severe rheumatoid arthritis
neovascularisation in adults
01.11.17 Roflumilast tab Amber 3.3.2 As per DPC 10/2017 Amend
Date Drug and formulation Colour
status
BNF
section
01.11.17 Enoxaparin inj Various 2.8.1 Note added to prescribe by
brand name as biosimilar
use
Amend
01.11.17 Optho-Lique eye drops Green 11.8.1 Add
01.11.17 Ropinirole MR tab Amber 4.9.1 Add
01.11.17 Ceftazidime/ Avibactam
cartilage defects of the knee
Add
refractory systemic anaplastic
Amend
eosinophillic asthma
severe rheumatoid arthritis
11.10.17 Neomycin eye oint Green 11.3.1 Removed from formulary as
formulation discontinued
27.09.17 Eluxadoline tab Amber 1.2 TA 471 Add
27.09.17 Oralvac compact
Second line therapy if Pollinex
not suitable
of priapism
27.09.17 Paclitaxel albumin inj Red 8.1.5 TA 476 Add
Date Drug and formulation Colour
status
BNF
section
TA 473 Amend
12.09.17 Ambrisentan tab Red 2.5.1 Only for patients already
commenced on therapy by
commenced on therapy by
criteria set by NHS England
Add
12.09.17 Cidofovir inf Red 5.3.2.1 For use as per commissioning
criteria set by NHS England
Add
criteria set by NHS England
Add
12.09.17 Deferasirox disp tab Red 9.1.3 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Deferiprone tab Red 9.1.3 For use as per commissioning
criteria set by NHS England
Add
criteria set by NHS England
Add
12.09.17 Icatibant inj Red 3.4.3 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Plerixafor inj Red 9.1.7 For use as per commissioning
criteria set by NHS England
Add
12.09.17 Sodium oxybate liq Red 4.1.1 For use in children as per
commissioning criteria set by
08.09.17 Dermol 500 lotion Green 13.2.1 Additional information “Note:
this contains an antimicrobial.
Not recommended for long-
blue.
Amend
status
BNF
section
Amended further information
as blue.
as blue.
once-daily dosing not
considered as non-formulary).
(licensed has been
discontinued, only available
licensed formulation (caps
maximum doses, as NICE no
longer specifies. Removed
updated and replaced by
foam in light of price increase
Add
Remove
30.08.17 Buspirone tab Amber 4.1.2 Change from red to amber
approved by DPC
Remove
approved by DPC
status
BNF
section
Comments Action
30.08.17 Insulin Aspart [Fiasp] inj Amber 6.1.1.1 Recommended by DPC. For
specialist recommendation.
30.08.17 Glucodrate powder Amber 9.2.1.2 Replacing St Mark’s solution.
Approved by DPC
30.08.17 Ketocal liquid N/A 9.4 Replacing ketocal powder Add
30.08.17 Anamix feeds N/A 9.4
Add
vaccine on routine schedule
schedule from Autumn 2017
30.08.17 Cabozantinib tab Red 8.1.5 TA 463 – For advanced renal
cell carcinoma in adults after
VEGF-targeted therapy
Add
30.08.17 Olaratumab inj Red 8.1.5 TA 465 – For use within the
CDF as an option for soft
tissue sarcoma
30.08.17 Baricitinib tab Red 10.1.3 TA 466 – An option for
moderate to severe RA
glucose tolerance test due to
reduced glucose content
difficulties
Add
26.07.17 Oxycodone capsules Green 4.7.2 For patients unable to tolerate
liquid. Not for ward stock
Add
26.07.17 Hydrocortisone,
status
BNF
section
guidelines previously
orally where capsules are
unable to be given
26.07.17 Ustekinumab inj Red 1.5.3 TA 456 Amend
26.07.17 Pembrolizumab inj Red 8.1.5 TA 447 Amend
26.07.17 Etelcalcetide inj Red 9.5.1.2 TA 448 Add
26.07.17 Everolimus tab and
26.07.17 Blinatumomab inj Red 8.1.5 TA 450 Add
26.07.17 Ponatinib tab Red 8.1.5 TA 451 Add
26.07.17 Carfilzomib inj Red 8.1.5 TA 457 Add
26.07.17 Trastuzumab emtansine
26.07.17 Collagenase clostridium
26.07.17 Adalimumab
28.06.17 Diphenylcyclopropenone
previously agreed at DPC
specials list, previously
agreed at DPC
paste 0.1% - 15% w/w
specials list, previously
agreed at DPC
specials list, previously
agreed at DPC
status
BNF
section
specials list, previously
agreed at DPC
previously agreed at DPC
previously agreed at DPC
specials list, previously
agreed at DPC
28.06.17 Eosin solution 2% Red 13.12 Unlicensed ; as per BAD
specials list, previously
agreed at DPC
shared care agreement ‘off-
recurrence of breast cancer.
clinic.
use without specialist support.
28.06.17 Similac Alimentum N/A 9.4 Formula milk for CMPA. On
infant guidelines, cheaper
28.06.17 Nutramigen 1 and 2 N/A 9.4 Replaced by Similac
Alimentum
Remove
28.06.17 Certolizumab pegol inj Red 10.1.3 TA 445 Amend
28.06.17 Secukinumab inj Red 10.1.3 TA 445 Amend
Date Drug and formulation Colour
status
BNF
section
28.06.17 Levosimendan inj Red 2.1 Specialist use only Add
28.06.17 Obeticholic acid tab Amber 1.9.1 NICE TA 443 Add
24.05.17 Dexamethasone soluble
removed from formulary. No
prescribed by GPs
24.05.17 Amiclair protein remover Red 11.9
24.05.17 Saline spray Red 11.9
24.05.17 Boston advance Red 11.9
24.05.17 Netupitant/Palonosetron
[Akynzeo] capsules
Red 4.6
24.05.17 Fondaparinux inj Red 2.8.1 New indication for superficial
thrombophlebitis
Amend
recommendation
Add
24.05.17 Daclizumab inj Red 8.2.4 NICE TA 441 Add
24.05.17 Ixekizumab inj Red 13.5.3 NICE TA 442 Add
19.04.17 Adapalene 0.1%,
benzoyl peroxide 2.5%
vulgaris. Positive
19.04.17 Pilocarpine eye gel Amber 11.6 Discontinued 2012. Not used
since then as alternative eye
drops are available
laryngotracheobronchoscopy
Amend
19.04.17 Diclofenac inj Red 15.1.4.2 Restricted to use in paediatric
theatres
Add
status
BNF
section
units/ml
out by specialists
30.03.17 Benzoyl peroxide 4%
replace with
item below
30.03.17 Benzoyl peroxide gel Green 13.6.1 To replace Brevoxyl (see
above)
Add
“Prescribe by brand name” as
new brand now available
new patients on Braltus brand
(lower cost).
13.6.2
formulary.
Remove
Useful for patients with dry,
sensitive skin and same cost
as gel.
only.
OTC.”
formula).
Amend
Date Drug and formulation Colour
status
BNF
section
01.03.17 Ivermectin cream Green 13.6.3 First line option for the
treatment of Papulopustular
31.01.17 Dasatinib, nilotinib and
31.01.17 Pomalidomide cap Red 8.1.5 NICE TA 427 Add
31.01.17 Pembrolizumab inf Red 8.1.5 NICE TA 428 Amend
31.01.17 Ibrutinib cap Red 8.1.5 NICE TA 429 Add
31.01.17 Sofosbuvir/velpatasvir
31.01.17 Mepolizumab inj Red 3.4.2 NICE TA 431 Add
31.01.17 Mannitol inhalation
bronchial
hyperresponsiveness
Add
patients with distal disease.
Second line treatment for
amber for all other
with other local organisations
(e.g. West Hants CCG,
status
BNF
section
14.12.201
6
14.12.201
6
14.12.201
6
Technologies guidance) 3
a steroid sparing agent at
step 4/5 of the BTS guidelines
Add
14.12.201
6
per chronic constipation
Pancrex V granules Amber 1.9.4 For use in patients who
require administration of
with severe myoclonic
14.12.201
6
14.12.201
6
14.12.201
6
14.12.201
6
14.12.201
6
Emtricitabine/tenofovir
tab
specialist only. As per local
commissioning arrangements
Remove branding
status
BNF
section
macrolide – follow guideline
23.11.201
6
23.11.201
6
26.10.201
6
Specialist initiation only for
Amend
26.10.201
6
26.10.201
6
number)
26.10.201
6
number)
26.10.201
6
number)
26.10.201
6
Talimogene
6.6).
at UHS.
UHS for patients with
Syndrome Protocol)
rhinitis where response to
status
BNF
section
an option for pre-operative
treatment of uterine fibroids
or for intermittent treatment
line therapies are
care only
indications)
Add
11.10.201
6
requested by DPC (safety
paediatric patients only.
primary care)
aciclovir eye oint is
other oral iron preparations
guidance/in response to
28.09.201
6
28.09.201
6
Date Drug and formulation Colour
status
BNF
section
2014
Remove
28.09.201
6
difficulties/enteral feeding
care only
17.08.201
6
17.08.201
6
17.08.201
6
patients already stabilised on
the one monthly depot.
those with swallowing
patients treated by the
17.08.201
6
17.08.201
6
17.08.201
6
17.08.201
6
17.08.201
6
centre, prior to capillary blood
gas sampling
status
BNF
section
17.08.201
6
17.08.201
6
therapy who become nil by
mouth
Add
17.08.201
6
shared care agreement with
the Royal Brompton hospital
22.6.2016 Brivaracetam tab/liq/inj Amber Not
listed
Add
22.6.2016 Cabazitaxel inj Red 8.1.5 NICE TA391 Add
22.6.2016 Canagliflozin,
dapagliflozin and
empagliflozin tablets
status
BNF
section
administration”
Amend
22.6.2016 5-aminolevulinic acid
11.6.2013
Add
22.6.2016 Mirabegron MR tab Green 7.4.2 NICE TA 290 – Listed as
green and amber on current
formulary, status should be
8.3.4.2
synonym for this medicine.
not meeting protein
requirements with standard
not meeting energy
requirements within the
enteral feed
supply to be initiated in
secondary care and then
continued in primary care.
status
BNF
section
added TA
TA91/222.
Amended,
Unlicensed product last used
number 20.4.16 Etanercept biosimilar inj
[Benepali]
20.4.2016 Nortriptyline tab Green 4.3.1 &
4.7.3
No longer recommended in
NICE Guidance or local
Remove TA132
23.3.2016 Nivolumab inj [Opdivo] Red 8.2.4 TA384 Added, with TA
number
status
BNF
section
13.5.3
confusion as biosimilar now
number
only.
tolerate danazol
able to obtain stocks of this
drug)
Added
status
BNF
section
only.
at UHS.
years)
Added
recommended locally for
2014, but not actioned.
psychiatric care.
2014, but not actioned.
17.2.2016 Esomeprazole inj Red 1.3.5 In UHS: Child Health only
[Pantoprazole remains as
patients]
Added
added TA
added TA
added TA
added TA
added TA
status
BNF
section
added TA
added TA
added TA
number
added TA
number
Added, with TA
dabigatran is required for
17.2.2016 Degarelix 120mg inj Red 8.3.4.2 Consultant urologist use only
as a SINGLE DOSE (240mg)
in patients with naive prostate
cancer who present with
added TA
status
BNF
section
added TA
added TA
TA373 Amended,
added TA
added TA
added TA
number
20.1.2016 Ingenol gel [Picato] Green 13.8.1 Status change from amber to
green
Amended
30.12.201
5
Specialist use only
Specialist
initiation/recommendation
only
Amended,
line option, but may be
considered for patients with
with kidney impairment (see
SGLT-2 inhibitor for patients
Now green for prevention of
fractures in patients with
status
BNF
section
Specialist use only
Oncology only
Oncology only
Specialist use only
by manufacturers.
tablets in patients with
nasogastric tubes or children”
licensed indications.
18.11.201
5
18.11.201
5
as now licensed as a POM.
Amended
02.11.201
5
02.11.201
5
as included in new COPD
Guidelines.
Amended
status
BNF
section
option as included in new
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
COPD Guidelines.
Oncology only
07.10.201
5
status
BNF
section
outpatient induction of labour
only for multiple sclerosis’
approved)
Amended
07.10.201
5
multiple sclerosis
Removed phrase ‘For
numbers
07.10.201
5
Lidocaine plaster Red 15.2 ‘Off label’ use at UHS for
management of traumatic rib
fractures (refer to protocol).
07.10.201
5
manufacturers
Removed
07.10.201
5
that only the eye ointment is
unlicensed (eye drops now
other brands of insulin
glargine for new patients)
status
BNF
section
as a licensed preparation is
now available (Bramox).
Removed wording “for
Only in conjunction with
main entry to allow
Amended.
(preservative-free)
Guidelines for Primary Care
Removed brand name
eye drops
(Brand name not specified in
main entry to allow
Amended.
main entry to allow
Amended.
status
BNF
section
Guidelines for Primary Care
Removed ‘Unlicensed’ as now
available as a licensed
Guidelines for Primary Care
Guidelines for Primary Care
Guidelines for Primary Care
Guidelines for Primary Care
added TA
that approved by NICE.
guideline
only in selected patients (e.g.
high risk of multiple or flat
tumours)
Added
02.09.201
5
number
status
BNF
section
number
02.09.201
5
NICE TA347.
of neuropathic pain ladder.
(Relatively high cost in
(Discussed at UHS Drugs
taken for DPC.
care therefore amitriptyline
remains first line)
preparation
preparation appears to
primary and secondary care)
Ferrous fumarate tab Green 9.1.1.1 Added phrase “First line oral
iron preparation”
Dermatology specialists no
“[Sinemet]” from main entry
other brands and generic
status
BNF
section
“[Stalevo]” from main entry
other brands now available.
clarification.
medicines should be
prescribed and supplied
patient is allergic to
option if patient is allergic to
commonly-used
preservatives”
Amended
Units/ml) as new, high
strength formulation now also
available (has same brand
Units/ml) as new, high
strength formulation now also
available (has same brand
Units/ml) as new, high
strength formulation now also
available (has different brand
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
status
BNF
section
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
For patients with cirrhosis
meeting NHS England criteria
for treatment of chronic
NICE TA330
manufacturers (2013)
29.06.15 Obinutuzumab inj Red 8.2.3 NICE TA343 Added, with TA
number
NICE TA337.
number
number
number, and
colour for
DVT/PE)
29.06.15 Darifenacin tab Green 7.4.2 First or second line option for
urinary incontinence.
29.06.15 Vedolizumab inj Red 1.5.3 For ulcerative colitis.
Specialist use only.
status
BNF
section
to green
to green and removed
line for new patients
29.06.15 Dulaglutide inj Green 6.1.2.3 Not a first-line option, but
may be considered for
for patients with kidney
Amber 11.8.1 Removed brand name Amended
04.06.15 Fortisip Bottle 200ml N/A 9.4 Moved from section 2 to
section 1 of UHS feeds and
nutritional supplements
03.06.15 Ciclosporin eye
drops unavailable
Hospital, Southampton.
Amber for prevention of
wording (‘For
NICE TA331
NICE TA329
Added BNF
status
BNF
section
NICE TA329
Added wording,
added TA
number
NICE TA117
macular oedema
Added TA
number and
29.04.15 Empagliflozin tab Green 6.1.2.3 NICE TA336 Added with TA
number
25.03.15 Miconazole 100mg
25.03.15 Ethinylestradiol
30microgram and
Marvelon
Amended
Mercilon
Amended
25.03.15 GlucoRx blood glucose
and Wavesense Jazz/Jazz Duo
blood glucose test strips
glucose test strips
glucose test strips
patients taking tapentadol MR
status
BNF
section
patients meeting NHS
second-line subcutaneous
25.02.15 Dolutegravir tabs Red 5.3.1 Specialist use only Added
25.02.15 Lithium carbonate MR
with shared care guidelines
25.02.15 Saxagliptin tabs Green 6.1.2 Replaced by alogliptin Removed
25.02.15 Alogliptin tabs Green 6.1.2 To replace saxagliptin Added
25.02.15 Dabigatran tabs
the treatment and secondary
prevention of deep vein
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
status
BNF
section
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
feeds and nutritional
2 of oral
2 of oral
status
BNF
section
28.01.15 Clinitest reagent tabs Discontinued by manufacturer Removed
07.01.15
(Decembe
r
meeting)
Erythropoiesis-
number 07.01.15
Imatinib tablets Red 8.1.5 According to NICE TA326 Added TA
number
07.01.15
(Decembe
r
meeting)
26.11.14 Dihydrocodeine MR
26.11.14 Tramadol MR
Date Drug and formulation Colour
status
BNF
section
26.11.14 Osvaren tablets
26.11.14 Co-codamol 30/500
Green 4.7.1 Changed from blue to green Changed
26.11.14 Ibuprofen gel Green 10.3.2 Changed from blue to green Changed
26.11.14 Metformin sachets Discontinued by
manufacturer. Some wards
Removed
20.10.14 Lenalidomide capsules Red 8.2.4 According to NICE TA322 Added
20.10.14 Carbamazepine
chewable tablets
(Tegretol Chewtabs)
29.9.14 Budesonide MDI Discontinued by manufacturer Removed
29.9.14 Adrenaline
(epinephrine) inhaler
[Primatene Mist]
echinocandin, caspofungin is
for stimulation of lactation,
licensed indications. Local
recommendation is 10mg
days, then stop. Contra-
indicated in patients with
status
BNF
section
1.9.14
(August
meeting)
BNF for
patients with Raynaud’s
phenomenon
Added
1.9.14
(August
meeting)
Choice of NRT patch Green 4.10.2 Change from NiQuitin CQ to
Nicorette Invisi patches
1.9.14
(August
meeting)
BNF
red
Changed
1.9.14
(August
meeting)
Co-amoxiclav
have failed to respond to, or
are intolerant of, other
options, or have psychological
distress due to persistent
redness. Cautious use is
available around long-term
effect with longer-term use.
worsening of their rosacea
status
BNF
section
1.9.14
(August
meeting)
Prasugrel tablets Amber 2.9 According to NICE TA317 Changed TA
number
1.9.14
(August
meeting)
1.9.14
(August
meeting)
1.9.14
(August
meeting)
1.9.14
(August
meeting)
formulary entry
mono-
falciparum malaria
falciparum malaria or as oral
step-down treatment
21.7.14 Emerade pre-filled pen Green 3.4.3 Supply problems with other
brands of adrenaline for self-
administration
Added
status
BNF
section
replaced by ‘unit dose eye
drops’ to allow purchasing of
different brands
craniotomy.
label status and lack of
comparative evidence and
an alternative
use only in Solent.
severe behavioural insomnia
30.6.14 Afatinib tablets Red 8.1.5 According to NICE TA310 Added
30.6.14 Bortezomib injection Red 8.1.5 According to NICE TA311 Added TA
number
in BNF
30.6.14 Alemtuzumab infusion Red 8.2.3 The old formulation of
alemtuzumab, used for bone
marrow transplant patients, is
named patient drug
30.6.14 Glyceryl trinitrate buccal
required
30.6.14 Forceval Junior Soluble Green 9.6.7 Replace formulation Changed from
Foreceval
primary care guideline
status
BNF
section
primary care guideline
amber to green
30.6.14 Dapagliflozin tablets Green 6.1.2.3 To be used in line with NICE
TA288
intolerant of preservatives
women with high BMI or
intrauterine device is declined
hours after intercourse)
formulary entry for nocturnal
cannot use other inhaler
dose to propionate 500
micrograms twice a day
COPD.
Note:
of neurological adverse
status
BNF
section
See MHRA Drug Safety
psychiatric care. Criteria for
use are being developed
28.4.14 Pixantrone injection Red 8.1.2 According to NICE TA306 for
non-Hodgkin’s lymphoma
28.4.14 Aflibercept injection Red 11.8.2 According to NICE TA305 for
macular oedema (central
retinal vein occlusion)
28.4.14 Rituximab infusion Red 8.2.3 According to NICE TA308 for
anti-neutrophil cytoplasmic
antibody-associated vasculitis
Added TA
10.1.3
Added
swallowing, who are nil by
mouth or who require
orally or through a gastric or
jejunal enteral feeding tube.
who are at risk of refeeding
syndrome, with poor wound
healing or who need
treatment for vitamin and
available and can be used
when clinicians choose to
prescribe off-label for patients
diabetic macular oedema
status
BNF
section
reported back to DPC
patients stabilised by
adequately responding to
treatment with monotherapy
in BNF
active relapsing-remitting
multiple sclerosis
20.1.14 Zoledronic acid 4mg
acid will replace pamidronate
16.12.13 Amoxicillin capsules Red 5.1.1.3 For patients with chronic low
back pain associated with
Modic type 1 changes
16.12.13 Fidaxomicin tablets Amber 5.1.7 Change from red to amber.
On advice of microbiology for
first episode of severe C. diff
on concomitant antibiotic or
16.12.13 Magnesium
16.12.13 Apomorphine injection Red for
new
patient
s
ordinated transfer to
16.12.13 Linaclotide capsules Amber 1.6.7 According to local algorithm Added
16.12.13 Immediate release
women or patients with
status
BNF
section
TA300 (hepatitis C, children
TA300 (hepatitis C, children
(choroidal neovascularisation
[pathological myopia])
(vitreomacular traction)
indications has been updated
(see end of document)
28.10.13 Mercaptopurine tablets Change
azathiorpine/mercaptopurine
macular degeneration
visual acuity <20/32).
preferred product as it is the
least expensive and contains
the correct combination of
vitamins and zinc. Unlike
longer contains beta-
no convincing evidence to
purchase these OTC.
normally initiated on
secondary care advice.
status
BNF
section
endoscopy for a specific group
of adults and children over 10
years who do not tolerate IV
cannulation (e.g. those with
the first line option for the
majority of patients
hypogonadism with marked
clinical symptoms of
nutrition
section
Added
2.9.13 Mirabegron tab Green 7.4.2 According to NICE TA290 Added NICE TA
number.
status
BNF
section
Comments Action
2.9.13 Ceftaroline inj Red 5.1.2 Only for specialist use on the
advice of microbiology
2.9.13 Eltrombopag tab Red 9.1.4 According to NICE TA293 Added
2.9.13 Eptotermin alfa
2.9.13 Dapagliflozin tab Amber 6.1.2.3 According to NICE TA288 Added
2.9.13 Aripiprazole tab Amber 4.2.1 According to TA292 (bipolar
disorder in children)
(pulmonary embolism and
fungal infections.
Note
which has been discontinued
29.7.2013 Calcium carbonate
unavailable
Added
29.7.2013 Hydroxyethyl starch
because large RCTs have
renal dysfunction and
septic patients who received
status
BNF
section
(FP10
use
only)
red to amber
red to amber
24.6.2013 Fidaxomicin tabs Red 5.1.7 Limited to patients with first
episode of severe C diff when
concurrent antibiotics cannot
episodes of C diff. On advice
of microbiology
degeneration according to
specialists
subtrochanteric fractures
Change
24.6.2013 Omalizumab inj Red 3.4.2 According to NICE TA278 Update NICE
TA number
(macular oedema)
24.6.2013 Pirfenidone caps Red 3.11 According to NICE TA282 Added
24.6.2013 Abatacept inj Red 10.1.3 According to NICE TA280
(rheumatoid arthritis)
Update NICE
TA number
status
BNF
section
20.5.13 Adcal chewable tab Green 9.5.1.1 Will replace Calcichew Changed
20.5.13 Adcal D3 effervescent
Green 9.6.4 Will replace Calfovit sachets Changed
20.5.13 Adcal D3 chewable tab Green 9.6.4 Will replace Calcichew D3
Forte
Changed
cannot tolerate chewable or
20.5.13 Oxazepam tab Amber 4.10.1 For use according to the
emergency department policy
on alcohol misuse
29.4.13 Dabigatran cap Green 2.8.2 Previously amber for
prevention of stroke in
green as GPs don’t refer these
patients to a specialist
prevention of stroke in
green as GPs don’t refer these
patients to a specialist
29.4.13 Apixaban tab Green 2.8.2 NICE TA275 for prevention of
stroke and systemic embolism
in patients with non-valvular
macular oedema
publication of NICE TA
receptor agonist for new
patients instead of exenatide
specialist for difficult to
diabetes
Added
29.4.13 Linagliptin tab Green 6.1.2.3 For patients with any stage of
renal impairment
status
BNF
section
Cerazette
Added
29.4.13 Octasa MR tab Amber 1.5.1 New name for Mesren Changed
29.4.13 Halothane Red 15.1.2 Has been discontinued Remove
25.2.13 Testosterone patch Blue 6.4.2 Had been discontinued, but
now available from a new
supplier
Re-instated
25.2.13 Choriogonadotropin alfa
25.2.13 Fluticasone and
patients age 6 and over with
cystic fibrosis and G551D
abstinence in alcohol
which device the patient can
use and cost
which device the patient can
use and cost
25.2.13 Voractiv tab Red 5.1.9 As complete courses of drugs
for TB are managed by the
hospital, all drugs in section
5.1.9 of the formulary will
become ‘red’
Added Voractiv.
5.1.9 amended
status
BNF
section
25.2.13 Argatroban inj Red 2.8.1 An option for patients in
critical care areas with
25.2.13 Eplerenone tab Amber 2.2.3 To reduce the risk of
cardiovascular mortality and
25.2.13 Ipilimumab infusion Red 8.1.5 According to NICE TA268 Added
25.2.13 Vemurafenib tab Red 8.1.5 According to NICE TA269 Added
25.2.13 Mannitol caps for
21.1.13 Ivabradine tab Amber 2.6.3 According to NICE TA267 Updated
21.1.13 Methylthioninium
during surgery.
Methylthioninium chloride
patients with
21.1.13 Darunavir liquid Red 5.3.1 GUM and Child Health
specialists only
of abstinence in alcohol
formulary. Now in 6.1.5 too,
for use in patients with
hyperhidrosis
Updated
radionuclide DOTATATE
Geltears
Updated
status
BNF
section
during surgery.
Methylthioninium chloride
patients with
malathion aqueous liquid,
green
Updated
12.11.12 Glatiramer injection Red 8.2.4 As part of the Department of
Health’s risk sharing scheme
for patients with multiple
15.10.12 Alteplase injection Red 2.10.2 Update to NICE guidance for
acute ischaemic stroke. Now
15.10.12 Prucalopride tablets Amber 1.6.7 According to shared care
guideline (available from
transfer from Epipen to Jext
(this device has a longer shelf
life)
Added
ed
secondary care for small
number of patients with
formulary
status
BNF
section
on long-term TPN or IV fluids
Added
17.9.12 Naltrexone tablets Amber 4.10 For alcohol addiction Previously used
at Southern,
drops (Hylo-Tear &
allergy to preservatives
Added
17.9.12 Travoprost eye drops Amber 11.6 For patients with a proven
allergy to benzalkonium
17.9.12 Loteprednol eye drops Amber 11.4.1 Added
17.9.12 Ulipristal 5mg tablets Amber 6.4.1.2 An option for the pre-
operative treatment of uterine
used in primary care. Efudix
remains the first-line topical
treatment (awaiting update of
superseded by NICE
ointment
discontinued
Added
17.9.12 Rivaroxaban tablets Green 2.8.2 NICE TA261 -an option for
treating DVT and long-term
Added
17.9.12 Botulinum toxin type A Red 4.9.3 Option for chronic migraine
according to NICE TA260
prostate cancer after
locally advanced or metastatic
status
BNF
section
stroke and systemic embolism
according to NICE TA249
17.9.12 Calcitonin nasal spray 6.6 Being discontinued due to risk
of cancer
seizure disorder
Added
17.9.12 Prucalopride tablets Amber 1.6.7 Changed from red to amber Changed
17.9.12 Ticagrelor tablets Green 2.9 NICE TA236 Changed colour
17.9.12 Rituximab infusion Red 8.2.3 NICE TA226 Added
17.9.12 Bivalirudin injection Red 2.8.1 NICE TA230 Added
17.9.12 Thalidomide capsules Red 8.2.4 NICE TA228 Added
17.9.12 Phenobarbital elixir Red 4.8.1 Unlicensed special order
preparations are available,
an excipient. Specialist only
prescribing and supplied from
18.6.12 Indapamide tablets and
now discontinued)
18.6.12 Omalizumab injection Red 3.4.2 Although ‘red’ locally it was
agreed that in order to reduce
day case attendances the 6
local patients receiving this
to teaching self-
administration to these
Added
status
BNF
section
18.6.12 Boceprevir capsules Red 5.3.3.2 According to NICE TA253 Added
18.6.12 Nilotinib capsules Red 8.1.5 According to NICE guidance
(TA251) as an option for first
line treatment of chronic
Added
18.6.12 Standard dose imatinib Red 8.1.5 According to NICE TA251 as
an option for first line
treatment of chronic myeloid
TA247 for rheumatoid
patients e.g active patients,
Red 3.4.2 According to NICE TA246 Added
18.6.12 Fingolimod capsules Red 8.2.4 Only according to NICE TA254 Added
18.6.12 Proveblue injection Red 15.2 Licensed version of
methylthioninium chloride
cohort of patients, in line with
current low priorities guidance,
on a table; and there is functional
impairment.
flexion. Only to be administered
by hand surgeons trained in its
use. Restricted to cases where it
is likely that only a single
Added
status
BNF
section
18.6.12 Rituximab injection Red 10.1.3 According to agreed guidance for
adults with systemic lupus
18.6.12 Growth hormone Red 6.5.1 First line choices are Omnitrope
and Genotropin. Consider
Genotropin
Updated
the licensed indications for
protection issues, generic
pioglitazone has demonstrated
on an exceptional basis for heavy
menstrual bleeding
following specialist
recommendation only
Southern Health
who need a different device
Added
fractured neck of femur or who
have a plaster cast and who fulfil
the assessment criteria
Added
(unlicens
ed)
Missed off formulary previously Added 26.3.12 Laxido Green 1.6.4 Previously ‘blue’ but now changed
to ‘green’ to promote use in UHS
for adults with chronic
constipation or faecal impaction
status
BNF
section
27.2.12 Goserelin, leuprorelin,
treatment and for the
indications
Changed
27.2.12 Easyhaler Formoterol Green 3.1.1.1 Added
27.2.12 Nevirapine MR tablets Red 5.3.1 Added
27.2.12 Rotigotine patches Amber 4.9.1 Initiated/recommended by
specialists: as a replacement for
oral dopamine agonists in
patients with inadequate control
medication, motor problems) and
situations when patients are
Changed
by NICE guidance)
drops
27.2.12 Sterile talc kit Red Not in
BNF
27.2.12 Rituximab injection Red 8.2.3 NICE TA243 – follicular
lymphoma
Added
idiopathic arthritis
by NICE guidance)
Added
23.1.12 PelvicToner device Blue As part of pelvic floor training Added
23.1.12 Levonorgestrel tablet 30
23.1.12 Ticagrelor tablet Blue 2.9 NICE TA236 Added
23.1.12 Mifamurtide injection Red 8.2.4 NICE TA235 Added
23.1.12 Estradiol vaginal tablet
Blue 7.2.1 Added
23.1.12 Nicorette Icy White Green 4.10.2 As part of smoking cessation Added
Date Drug and formulation Colour
status
BNF
section
23.1.12 Nicorette Quickmist
programme
Added 23.1.12 Nicorette Inhalator Green 4.10.2 As part of smoking cessation
programme
Added
23.1.12 Capsaicin patch 8% Red 10.3.2 Only for patients with post-
herpetic neuralgia who have
options
Added
12.12.11 Aminophylline MR tablet Green 3.1.3 For existing patients Added
12.12.11 Ferric carboxymaltose
indication of peripheral nerve
infusion via peripheral nerve
14.11.11 Golimumab injection Red 10.1.3 NICE TA233 Added
14.11.11 Moxifloxacin tablet Amber 5.1.12 Already on the formulary for
restricted use. Formulary entry to
be amended to add use according
to guideline (adult ENT)
Amended
17.10.11 TriRegol tablet Blue 7.3.1 To replace Logynon Added 17.10.11 Rigevidon tablet Blue 7.3.1 To replace Ovranette Added
17.10.11 Millinette 30/75 tablet Blue 7.3.1 To replace Femodene Added
12.09.11 Ciclosporin eye drops Red 11.8.1 A special Added
12.09.11 Golimumab injection Red 10.1.3 NICE TA225 Added
12.09.11 Retigabine tablets
brand of botulinum is required
and indication
Pharmacy.
(Oxynorm) liquid (green) in
accordance with the formulary.
their supply of Oxycodone
status
BNF
section
19.07.11 Romiplostim
19.07.11 Naftidrofuryl capsule Green 2.6.4 NICE TA223 Added
19.07.11 Denosumab injection Amber 6.6.2
NICE TA204 Added
19.07.11 Naltrexone tablet
alcohol withdrawal in patients
alcohol detox service
swallow tablets
13.06.11 Raltegravir tablet Red 5.3.1 Prescribing should be carried out
be local HIV specialists only
13.06.11 Maraviroc tablet Red 5.3.1 Prescribing should be carried out
be local HIV specialists only
13.06.11 GlucoRx test strips Blue 6.1.6
13.06.11 Osvaren tablet Blue 9.5.2.2 Hyperphosphataemia of chronic
renal failure in patients
statement “for pancreatic and
09.05.11 Fondaparinux injection Red 2.8.1 As an adjunct to thrombolysis
with tenecteplase in STEMI
experienced adults
syndromes
Added
18.04.11 Saxagliptin tablet Green 6.1.2.3 Another option for Type 2
Diabetes. Can be used in patients
with moderate to severe renal
impairment
Added
Marvelon whilst in short supply
Added.
Amended
18.04.11 Pazopanib tablet Red 8.1.5 According to NICE TA215 Added
18.04.11 Bendamustine injection Red 8.1.1 NICE TA216 – lymphocytic
leukaemia
Added
- drugs for treatment after failure
Added
status
BNF
section
18.04.11 Sirolimus tablet Amber 8.2.2 Prevention of rejection in post
liver transplant patients
18.04.11 Rosiglitazone tablet Green 6.1.2 Withdrawn from the UK Market
November 2010
Microbiology approved treatment
of mycobacterium abcessus
psoriasis. Topical treatment of
plaque psoriasis.
tablets in patients with NG tubes
or paediatric patients. Tab and
caps already on formulary
21.03.11 Venlafaxine tablet Green 4.3.4 Only high dose is amber
{previously all doses amber}
21.03.11 Aripiprazole tablet Amber 4.2.1 NICE TA213 Prescribing in 15-17
year old: schizophrenia
information
prior to surgery on enhanced
recovery programme
21.02.11 Tafluprost eye drops Amber 11.6 Specialist use and
recommendation.
preservative free prostaglandin
corneal grafts
21.02.11 Melatonin tablet/capsule Amber 4.1.1 Cost effective first line choice is
Biomelatonin tabs, followed by
Melatonin Biotec caps
neurogenic bowel dysfunction
other treatments have failed, or
when incontinence is a problem
Added
21.02.11 Liraglutide injection Amber 6.1.2.3 According to NICE TA203 For
Date Drug and formulation Colour
status
BNF
section
21.02.11 Trastuzumab injection Red 8.1.5 Gastric cancer according to NICE
TA208
For
Information
13.12.10 Botulinum Toxin
cumulative update
3
Dietitia
n
request
18.10.10 Pollinex Quattro®
clinic’s use only
18.10.10 Rosiglitazone tablet Green 6.1.2.3 MHRA alert. Removed from UK
market 21.10.10
by trained professionals
18.10.10 Calcium phosphate
sachet (Calfovit D3®)
vitamin D3 forte for patients
unable to swallow tablets
Added
18.10.10 Fondaparinux injection Red 2.8.1 For NSTEMI (NICE CG94) Amended
18.10.10 Nutricia Pre-op
replacement on enhanced
{Geltears®}
Amended
Syndrome
cystic fibrosis.
carmellose drops (Celluvisc®)
preservatives is problematic
by NICE TA211)
status
BNF
section
Comments Action
13.09.10 Abidec® drops Green 9.6.7 Used by neonatal unit as an
alternative to Dalivit drops
13.09.10 Vinorelbine capsule Red 8.1.4 Reserved for patients with poor
venous access as part of a
second or third line
chemotherapy regimen. In all
other circumstances, and for
exceptional cases, an Individual
Funding Request may be
18.07.10 NuvaRing®
contraceptive device
18.07.10 Insulatard InnoLet® Green 6.1.1.2 Treatment of gestational diabetes
and type 2 diabetes in pregnancy
Added
18.07.10 Darunavir 400mg tablet Red 5.3.1 In combination with ritonavir for
antiretroviral naïve patients
To be used in line with “Protocol
for use of sugammadex”
sclerosis (previously
methylprednisolone sodium
administered orally)
Added
Removed
antiemetics
Amended
units
26.04.10 Remifentanil injection Red 15.1.4.3 Patient controlled analgesia for
labour
Amended
(previously
theatres
only)
Added
discharge
Added
instillation is greater than 6 times
daily. Complete course to be
provided on discharge from
26.04.10 Certolizumab pegol Red 10.1.3 Option in severe active Added
Date Drug and formulation Colour
status
BNF
section
tried methotrexate and another
DMARD, according to NICE:
26.04.10 Trabectedin injection Red 8.1.5 Soft tissue sarcoma according to
NICE:
http://guidance.nice.org.uk/TA185
Added
26.04.10 Ferrous fumarate tablet Green 9.1.1.1 Currently PCT use only, change to
green
Amended
26.04.10 Ferrous sulphate Green 9.1.1.1 Replaced by ferrous fumarate Removed
26.04.10 Triclofos liquid Red 4.1.1 Discontinued Removed
26.04.10 Amphotericin lozenges Green 12.3.2 Discontinued Removed
End of list
Portsmouth Area Prescribing Committee
Blepharospasm √ √ √
Cervical dystonias √ √ √ √
Focal spasticity √ (arm & foot) √ (foot & post stroke wrist/hand) √ (post stroke arm)
Hemifacial spasm √ √
Hyperhidrosis (severe) √
Migraine prophylaxis √
sclerosis
Unlicensed: Ophalmology
Induction of ptosis to treat corneal exposure problems or facial palsy
Treatment of early onset squint
EMG guided intra ocular inj for diagnostic purposes such as checking for binocular potential prior to squint surgery
EMG guided intra ocular inj for therapeutic purposes such as inj into medial rectus & transpose vertical recti for cases of
complete VI nerve palsy
Face & neck tics
Spasm of reconstructed pharynx after laryngectomy
Spastic dysphonia
Gastro
Approved by Basingstoke, Southampton & Winchester DPC and Portsmouth APC 2013
(9.13)